Pay in 4 interest-free payments of $6.08 Learn more
Ships within 48 hours · Estimated delivery Oct 4 - Oct 9
The headline On Thursday 21 May 2026, Eli Lilly announced that participants in TRIUMPH-1, the first Phase 3 trial of retatrutide in obesity, lost an average of 28.3% of their body weight at 80 weeks on the 12 mg dose, with 45.3% losing at least 30% of their starting weight [1]
Some prescribers may consider semaglutide for off-label use in people with overweight or obesity, insulin resistance, or metabolic syndrome when they judge it appropriate
1 This regulatory difference means: No requirement for clinical trials proving safety or effectiveness Less stringent quality control standards Limited oversight of manufacturing processes Potential variations in potency and purity Effectiveness Comparison Clinical Trial Data for Ozempic Multiple large-scale studies support Ozempics effectiveness
They directed me to a small 35-person open-label, unpublished trial using subjective outcomes
US$ 27.72
US$ 22.34
US$ 24.19
US$ 23.84
US$ 26.51
US$ 22.31
US$ 23.18
US$ 27.50
US$ 24.32
US$ 29.30
US$ 27.69
US$ 28.27
US$ 20.93
US$ 26.93
US$ 27.95
